GFG
REGN icon

Greenbush Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Greenbush Financial Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301K Sell
483
-6
-1% -$4.08K 0.09% 31
2026
Q1 		$378K Buy
+489
New +$374K 0.13% 32

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Greenbush Financial Group's REGN Position: Q2 2026 in Review

Greenbush Financial Group reduced its Regeneron Pharmaceuticals (REGN) stake by 1.2% in Q2 2026, selling an estimated $4.08K and leaving 483 shares worth $301K. The position accounts for 0.09% of the portfolio, ranked #31.

Greenbush Financial Group first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $378K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Greenbush Financial Group held 483 shares of Regeneron Pharmaceuticals worth $301K as of Q2 2026.
  • Greenbush Financial Group sold 6 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.08K.
  • Regeneron Pharmaceuticals made up 0.09% of Greenbush Financial Group's portfolio in Q2 2026, its #31 holding.
  • Greenbush Financial Group first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Greenbush Financial Group's Regeneron Pharmaceuticals position peaked at $378K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Greenbush Financial Group's 13F filing for Q2 2026, filed 21 Jul 2026.